Medicine supplies and food safety standards are both vital and the EU cannot prioritise one over the other in the event of a no-deal Brexit, Vice President of the Commission Jyrki Katainen said on Thursday (4 April).
The European Commission’s much-awaited communication on the environmental impact of pharmaceuticals is at an “advanced stage” but might not be adopted in the near future because of other legislative initiatives on the agenda, an EU official has told EURACTIV.com.
Following a clash with the Greek government over its decision to withdraw a cancer drug from the market, ROCHE, a Swiss multinational company, ultimately decided to make the drug available to patients for free.
A multinational pharmaceutical company has decided to withdraw an innovative oncology medicine from the Greek market, claiming that its price has fallen more than 50% because of the government’s regulatory interventions in the pharma area, EURACTIV.com has learnt.
Backing innovation in the pharmaceutical market and developing new evidence-based economic models is the only way forward for future healthcare, according to EU Commissioner for Health and Food Safety Vytenis Andriukaitis.
The European Medicines Agency (EMA) presented on Tuesday (1 August) a business continuity plan aimed at tackling the potential challenges poised by its relocation from London to another member state after the Brexit decision.
Hosting the European Medicines Agency brings considerable economic benefits to the host city as the service employs more than 1,000 people, paid by the EU. Athens and Milan are keen to secure a slice of this lucrative pie.
Patient organisations warned the European Council yesterday (12 April) to be “vigilant” in the relocation of the European Medicines Agency (EMA), as well as avoid unnecessary delays that may cause disruptions in healthcare.
Controls on EU immigration played a key role in the Brexit vote. However, the UK government now says that it wants to protect the free movement of researchers and talent, which are crucial for the life sciences sector. EURACTIV.com reports from Lyon.
A European Parliament resolution adopted yesterday (2 March) called for transparency and clarity of public funding on research and development of new drugs, claiming that in such cases public investment should be reflected in the price of drugs.
France is leading calls for the G7 to act against the inflation of medicine prices. Treatment costs are rising in rich countries, but can be even higher in the developing world. EURACTIV France reports.
Europe's pharmaceuticals industry said on Tuesday (1 September) it had filed a complaint with the European Commission against a French law promoting the use of Roche's cancer drug Avastin as an alternative to more expensive eye treatments.
Paracetamol tablets are the world’s most commonly used painkillers. According to a recent study published in the British journal Annals of the Rheumatic Diseases, prolonged use of the drug can have very harmful side effects. EURACTIV France reports.